A detailed history of Nuveen Asset Management, LLC transactions in Annexon, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 2,555,570 shares of ANNX stock, worth $13.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,555,570
Previous 1,627,402 57.03%
Holding current value
$13.2 Million
Previous $7.97 Million 89.72%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.49 - $7.2 $4.17 Million - $6.68 Million
928,168 Added 57.03%
2,555,570 $15.1 Million
Q2 2024

Aug 09, 2024

BUY
$4.33 - $6.79 $5.71 Million - $8.96 Million
1,319,344 Added 428.28%
1,627,402 $7.97 Million
Q1 2024

May 13, 2024

BUY
$4.03 - $7.81 $457,243 - $886,122
113,460 Added 58.3%
308,058 $2.21 Million
Q4 2023

Feb 14, 2024

BUY
$1.63 - $4.63 $10,533 - $29,919
6,462 Added 3.43%
194,598 $883,000
Q2 2023

Aug 14, 2023

BUY
$2.1 - $6.37 $395,085 - $1.2 Million
188,136 New
188,136 $662,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $351,954 - $677,220
-166,803 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$2.73 - $11.94 $153,958 - $673,356
56,395 Added 51.08%
166,803 $570,000
Q4 2021

Feb 14, 2022

SELL
$11.49 - $22.0 $94,849 - $181,610
-8,255 Reduced 6.96%
110,408 $1.5 Million
Q3 2021

Nov 12, 2021

SELL
$16.35 - $23.4 $104,394 - $149,409
-6,385 Reduced 5.11%
118,663 $2.63 Million
Q2 2021

Aug 16, 2021

BUY
$17.81 - $27.48 $680,057 - $1.05 Million
38,184 Added 43.96%
125,048 $2.81 Million
Q1 2021

May 17, 2021

BUY
$22.0 - $35.01 $511,918 - $814,647
23,269 Added 36.59%
86,864 $2.42 Million
Q4 2020

Feb 16, 2021

BUY
$20.81 - $30.55 $438,445 - $643,657
21,069 Added 49.54%
63,595 $1.59 Million
Q3 2020

Nov 16, 2020

BUY
$17.5 - $30.23 $744,205 - $1.29 Million
42,526 New
42,526 $1.29 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $246M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.